All In Biotech

Drug Trial Radar · NCT02760264

A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

Last checked: Nov 19, 2026Latest source record: Jan 2, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

48

Actual

Start

Jun 2016

Primary completion

May 1, 2018

Study completion May 1, 2018

Sponsor

Lead sponsor
ReveraGen BioPharma, Inc.Industry
Sponsor type
Industry
Collaborators
University of Pittsburgh; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); National Institute of Neurological Disorders and Stroke (NINDS); Cooperative International Neuromuscular Research Group
First posted
May 3, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 4 years, up to 6 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether a new medication called vamorolone is safe and well-tolerated by boys with Duchenne muscular dystrophy (DMD) ages ≥ 4 and \< 7 years old.

Conditions

  • Duchenne Muscular Dystrophy

Interventions

  • Vamorolone 0.25 mg/kg/dayDrug

    Oral administration of 0.25 mg/kg/day daily for 14 days.

  • Vamorolone 0.75 mg/kg/dayDrug

    Oral administration of 0.75 mg/kg/day daily for 14 days.

  • Vamorolone 2.0 mg/kg/dayDrug

    Oral administration of 2.0 mg/kg/day daily for 14 days.

  • Vamorolone 6.0 mg/kg/dayDrug

    Oral administration of 6 mg/kg/day daily for 14 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Summary of Adverse Events as Assessed by CTCAE Version 4.03Time frame: Adverse events will be recorded from the date of informed consent and through the time of the subject's last study visit. Serious adverse events will be recorded from the date of informed consent and for up to 30 days after final drug administration.

Locations

12 sites in 6 countries. Site status is shown where the registry gives one.

  • University of California Davis

    Davis, California

  • University of Florida

    Gainesville, Florida

  • Nemours Children's Hospital

    Orlando, Florida

  • Ann & Robert H. Lurie Children's Hospital

    Chicago, Illinois

  • Duke University

    Durham, North Carolina

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • Royal Children's Hospital

    Melbourne, Australia

  • Sydney Children's Hospital

    Westmead, Australia

  • Alberta Children's Hospital

    Calgary, Alberta, Canada

  • Schneider Children's Medical Center

    Petah Tikvah, Israel

  • Queen Silvia Children's Hospital

    Gothenburg, Sweden

  • Newcastle upon Tyne Hospitals NHS Foundation Trust

    Newcastle upon Tyne, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.